|Bid||68.50 x 1000|
|Ask||78.57 x 900|
|Day's Range||69.19 - 71.83|
|52 Week Range||54.48 - 74.92|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||140.74|
|Earnings Date||Jan 22, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||1.12 (1.64%)|
|1y Target Est||79.44|
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]
Jim Cramer flies through his responses to callers' stock questions, including one about the prospects for a drugmaker's stock.
Boston Scientific’s stock moved 5.17% lower Tuesday, to close the day at $36.52. The stock recorded a trading volume of 8,966,181 shares, which was above its three months average volume of 7,581,259 shares. In the last year, Boston Scientific’s shares have traded in a range of 24.54 - 39.44.
While AbbVie (NYSE:ABBV) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Although the concerns may be overblown, losing any patent protection on the widely prescribed drug breeds the type of uncertainty that often leads to stock declines. What gives investors confidence in the shares, though, is a promising drug pipeline should keep AbbVie stock on a growth trajectory even as Humira fades as a significant revenue contributor.
Biotech stocks, like the rest of the broader market, have been under heavy pressure in late 2018. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which includes several of the largest biotechnology stocks, and the SPDR S&P Biotech ETF (NYSEARCA:XBI), which also includes the sectors sector’s mid- and small-cap companies, have been in a free-fall since October, declining over 15% each. Although many of these biotech stocks, including AbbVie (NYSE:ABBV), Celgene (NASDAQ:CELG) and Mylan (NASDAQ:MYL), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet.
Chairman and CEO of Abbott Laboratories (NYSE:ABT) Miles D White sold 142,341 shares of ABT on 11/28/2018 at an average price of $72.35 a share.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would buy more DowDuPont Inc (NYSE: DWDP ). New York Mortgage Trust (NASDAQ: NYMT ) is too opaque, said Cramer. He finds it hard to ...
Vivian Maier is both elusive and ever-present in her photographs, clue and mystery wrapped up together in a series of Hitchcockian cameos. Maier kept her art secret, working for years as a nanny in the wealthy suburbs of Chicago. Enfeebled and impoverished in her eighties, Maier stopped paying the rent, so boxes of her stuff were cleared out and auctioned off in 2007.
Jim Cramer flies through his responses to callers' stock questions, including one on a massive industrial preparing for a corporate split.
In November 2018, of the total 15 analysts covering Align Technology (ALGN), 13 analysts have given Align stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Align Technology stock is 1.67 with a target price of $317.36, implying an upside potential of 43.8% over Align Technology’s closing price of $220.71 on November 27, 2018.
Align Technology (ALGN) is focused on establishing its Invisalign clear aligners as the standard method for treating malocclusion and establishing its iTero intraoral scanner as the scanning device of choice for 3D digital scans.
For fiscal 2018 and 2019, Align Technology’s gross margins are expected at 73.97% and 73.69%, respectively, as compared with gross margins of 75.81% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Abbott Laboratories (ABT), Boston Scientific (BSX), and Edwards Lifesciences (EW) are expected at 59.29%, 72.08%, and 74.83%, respectively.
A strong operational performance and steady uptick in Edwards Lifesciences’ (EW) stock price has kept investors interested in the stock in 2018. In this series, we’ll discuss Edwards Lifesciences’ financials, segmental performance, analysts’ views on the stock, and the company’s valuation metrics. Edwards Lifesciences is a leader in patient-focused solutions for structural heart disease and critical care monitoring.
Edwards Lifesciences’ (EW) cost of sales increased from $213.3 million in the third quarter of 2017 to $224.9 million in the third quarter. The company’s gross profit grew from $608.2 million in the third quarter of 2017 to $681.7 million in the third quarter due to the improved product mix.
How's Dentsply Positioned in November? Dentsply Sirona’s (XRAY) cost of products sold increased marginally from $450.2 million in the third quarter of 2017 to $452.3 million in the third quarter. For fiscal 2018 and 2019, Dentsply’s gross margins are expected to be 55.04% and 55.29%, respectively—compared to its gross margins of 54.80% for fiscal 2017.
Dentsply Sirona’s (XRAY) interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter. The company’s interest income increased from $400,000 in the third quarter of 2017 to $600,000 in the third quarter. Dentsply’s net other expense increased from $900,000 in the third quarter of 2017 to $4.7 million in the third quarter. The company’s provision for income taxes decreased from $7.1 million in the third quarter of 2017 to $4.2 million in the third quarter.
Among the 15 analysts covering Dentsply Sirona (XRAY) in November, five analysts gave a “buy” or a higher recommendation, while ten analysts gave a “hold” recommendation. The mean rating for Dentsply stock is 2.53 with a target price of $46.73, which implies an upside potential of 28% over the closing price of $36.51 on November 23. Peers’ ratings
Dentsply Sirona (XRAY) is a global manufacturer of professional dental products and technologies. Dentsply operates in two business segments—the Consumables and Technologies segment and the Equipment segment. Sales from the Technologies and Equipment segment, which includes dental implants, imaging systems, treatment centers, and consumable medical device products, decreased from $558.5 million in the third quarter of 2017 to $495.2 million in the third quarter.